文献速递肝病

慢性乙型肝炎长期核苷酸类似物治疗停药:HBRN免疫活动期治疗试验停药阶段结果

Withdrawal of Long-Term Nucleotide Analog Therapy in Chronic Hepatitis B: Outcomes From the Withdrawal Phase of the HBRN Immune Active Treatment Trial.
PubMed 文献 · Am J Gastroenterol · 2023-01-13

HBRN免疫活动期试验评估替诺福韦治疗4年(±初始6个月聚乙二醇干扰素α)后停药,201例中97例停药并随访至少1年。停药后2年内HBsAg清除累积率4.3%,37.1%出现ALT flare,13.4%需重启治疗。结果不支持将替诺福韦停药作为治疗策略,若考虑停药应在HBV DNA>4 log10 IU/mL时重启治疗以减少ALT flare风险。

要点

  • 停药后2年内HBsAg清除累积率仅4.3%,不支持替诺福韦停药作为治疗策略。
  • 停药后37.1%出现ALT flare(>5×ULN),与1年和2年时免疫活动性疾病相关。
  • 13.4%需重启治疗;若考虑停药,HBV DNA>4 log10 IU/mL时应重启治疗。

核心结论

  • 本试验结果不支持将替诺福韦停药作为治疗策略;停药后2年内HBsAg清除不常见。
  • 若考虑停药,应仔细监测HBV DNA,若水平升至4 log10 IU/mL以上应重启治疗以降低ALT flare风险,因ALT flare与后续HBsAg下降或清除无关。

研究设计与样本

  • HBRN免疫活动期试验(NCT01369212)评估替诺福韦治疗4年±初始6个月聚乙二醇干扰素α后停药。
  • 符合条件者为HBeAg阴性/抗-HBe阳性、HBV DNA<10^3 IU/mL、无肝硬化且停用替诺福韦的参与者,随访至少1年,之后可选继续随访。
  • 重启治疗基于预设标准。

主要发现

  • 201例接受4年治疗者中97例停药(替诺福韦组45例,替诺福韦+聚乙二醇干扰素α组52例,79例为亚洲人)。
  • 5例发生HBsAg清除,其中2例在停药后25周内、3例在停药后89-119周内,2年累积率4.3%。
  • 停药后ALT flare(>5×正常上限)发生于36例(37.1%),治疗开始时HBeAg阴性者较HBeAg阳性者更频繁且更早发生。
  • ALT flare与年龄较大及治疗前和flare前访视时HBV DNA较高相关;ALT flare与HBsAg下降或清除无显著关联,但与停药后1年(70.6% vs 11.9%,P<0.0001)和2年(66.7% vs 25.9%,P=0.03)免疫活动性疾病相关。
  • 13例(13.4%)需重启治疗,另13例在研究随访结束时维持持续非活动携带状态。

关键数值与推荐

  • ALT flare定义为>5×正常上限。
  • 若考虑停药,HBV DNA升至4 log10 IU/mL以上时应重启治疗。
  • 无标准能可靠预测安全停药。

临床怎么用

  • 作者认为本试验结果不支持将替诺福韦停药作为治疗策略。
  • 作者建议若考虑停药,应仔细监测HBV DNA,若水平升至4 log10 IU/mL以上应重启治疗以降低ALT flare风险。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: Withdrawal of nucleos(t)ide analog therapy is increasingly being evaluated in chronic hepatitis B infection as a strategy to induce hepatitis B surface antigen (HBsAg) loss. The Hepatitis B Research Network Immune-Active Trial evaluated treatment with tenofovir (TDF) for 4 years ± an initial 6 months of peginterferon-α (PegIFN) (NCT01369212) after which treatment was withdrawn. METHODS: Eligible participants (hepatitis B e antigen [HBeAg]-/anti-HBe+, hepatitis B virus [HBV] DNA <10 3 IU/mL, no cirrhosis) who discontinued TDF were followed for at least 1 year with optional follow-up thereafter. Retreatment was based on predefined criteria. RESULTS: Among 201 participants who received 4 years of treatment, 97 participants (45 TDF and 52 TDF + PegIFN arm, 79 Asian) discontinued TDF. HBsAg loss occurred in 5 participants, 2 within 25 weeks and 3 within 89-119 weeks postwithdrawal (cumulative rate 4.3% by 2 years). Alanine aminotransferase (ALT) flares (>5× upper limit of normal) after TDF withdrawal occurred in 36 (37.1%) participants and occurred more frequently and earlier in those HBeAg- compared with HBeAg+ at treatment initiation. ALT flares were associated with older age and higher HBV DNA pretreatment and at the visit before the flare. ALT flares were not significantly associated with HBsAg decline or loss but were associated with immune active disease at 1 year (70.6% vs 11.9%, P < 0.0001) and 2 years (66.7% vs 25.9%, P = 0.03) postwithdrawal. Treatment reinitiation was required in 13 (13.4%) participants, and 13 others remained in a sustained inactive carrier state by the end of the study follow-up. No criteria reliably predicted safe treatment withdrawal. DISCUSSION: Results from this trial do not support TDF withdrawal as a therapeutic strategy. HBsAg loss was infrequent within 2 years of stopping long-term TDF. If withdrawal is considered, HBV DNA should be carefully monitored with reinitiation of therapy if levels rise above 4 log 10 IU/mL to reduce the risk of ALT flares, as they were not associated with subsequent HBsAg decline or loss.

来源:Am J Gastroenterol,查看原文。版权归原作者所有。

引用

  1. Feld JJ, Wahed AS, Fried M, et al. Withdrawal of Long-Term Nucleotide Analog Therapy in Chronic Hepatitis B: Outcomes From the Withdrawal Phase of the HBRN Immune Active Treatment Trial. Am J Gastroenterol. 2023. PMID: 36728214. doi:10.14309/ajg.0000000000002176

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。